NEW YORK (GenomeWeb) – Signal Genetics today announced that is has signed an agreement to make its MyPRS assay available to 22 million patients covered by America's Choice Provider Network (ACPN).

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.